The PRIME-ROSE consortium will be actively present at the upcoming ESMO Congress 2025 in Berlin (17–21 October), highlighting its commitment to advancing precision cancer medicine through pragmatic clinical trials and cross-border collaboration. Several consortium members will present cutting-edge research and policy insights across various sessions.

‍

🔬Scientific Contributions

• Mini Oral Session
      🗓 Saturday 18 October, 08:30–10:00
      1140MO – Clinical benefit of genomic-guided targeted therapies in patients with rare cancers: First results from the IMPRESS-Norway trial
      🎤 Katarina Puco (Oslo, Norway)
• Proffered Paper Session: Policy
      🗓 Saturday 18 October, 14:45–16:15
      2273O – Routes for access to off-label treatments: a comparative analysis of 19 European countries
      🎤 Atse Huisman (Leiden, Netherlands)
• Young Oncologists Brunch 2
      🗓 Sunday 19 October, 10:30–11:15
      Drug repurposing trials: What are they and where are they going?
      🎤 Kjetil Taskén (Oslo, Norway)

‍

• Poster Presentations

🗓 Sunday 19 October, 12:00-12:45

o  989P – Efficacy of molecularly matched, targeted therapies outside current drug indications: Results from the first 301 patients treated in the ProTarget Trial –Tina Kringelbach

🗓 Monday 20 October, 12:00-12:45

o  149P – Circulating tumorDNA versus tissue profiling for therapy selection in advanced cancer: Resultsfrom the IMPRESS-Norway trial – Ingrid Dyvik

o  162P – Nationwide implementation of comprehensive genomic profiling in advanced cancer: The first 1,740 patients included in the IMPRESS-Norway profiling phase – Ingrid Dyvik

o  165P – Diversity in Treatment Benefit between Adolescents and Young Adults (AYAs) and Older Adults(OA) treated in the Drug Rediscovery Protocol (DRUP) – Soemeya F. Haj Mohammad

o  2293P – High Off-Label Use in Paediatric Oncology: A Need for Policy Reform – Sahar B. van Waalwijk van Doorn-Khosrovani 

‍

• Proffered ‍Paper Session: AI & Digital Oncology
  🗓 Monday 20 October, 16:30–18:00
  3137O – IMPRESS-Norway: A Nationwide Precision-Oncology Study for Off-Label Targeted Therapies: Results From the First 1,740 Patients
  🎤 Sigmund Brabrand (Oslo, Norway)

‍

🤝 Consortium Engagement

These presentations reflect the consortium’s commitment to expanding the therapeutic landscape for patients with rare or refractory cancers.

PRIME-ROSE team has  already planned many collaboration meetings both with Pharma and research colleagues. These meetings will foster collaboration and strengthen the growing community of precision oncology researchers. Book your meeting from the link.

📢 PRIME-ROSE aims to

• Increase visibility of pragmatic clinical trials in precision oncology.
• Promote cross-border data sharing and policy harmonization.
• Engage stakeholders including regulators, patient organizations, and industry.

‍